Navigation Links
Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT)
Date:7/10/2014

t patients or discharge them on outpatient therapy.
  • Preference for oral antibiotics over OPAT: Oral therapies offer the potential to substantially simplify antibiotic treatment compared with therapies that are administered intravenously. Not surprisingly, surveyed ID specialists reported being more likely to prescribe oral formulations of both Cubist's Sivextro (tedizolid) and Tetraphase's emerging drug eravacycline when discharging patients than OPAT with either drug, suggesting oral formulations of these agents will see greater use as discharge therapy.
  • Comments from Decision Resources Group Analyst Hannah E. Cummings, Ph.D.:

    • "Hospitals are actively looking to cut costs and reduce or shorten admissions, and discharging patients on OPAT is an important part of their strategy. OPAT is a particularly attractive treatment modality for patients presenting to the emergency room with an infection requiring IV antibiotic therapy but not necessitating admission. ID specialists and emergency room physicians are frequently involved in identifying and recommending patients for OPAT and will likely be key stakeholders in driving uptake of new OPAT therapies."
    • "Surveyed ID specialists identified a need for new OPAT drugs for infections due to drug-resistant pathogens that are dosed once daily. Although the OPAT market is highly genericized, agents demonstrating benefits in efficacy, dosing-frequency and/or administration, such as Cubist's Cubicin (daptomycin) and Merck's Invanz (ertapenem), have experienced widespread use in the OPAT market. New agents will also have to demonstrate improvements on these key attributes to successfully compete in the OPAT market segment."

    About Decision Resources Group
    Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare indu
    '/>"/>

    SOURCE Decision Resources Group
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
    2. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
    3. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
    4. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
    5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
    6. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
    7. Applegate CEO Worries FDA Plan To Address Antibiotics In Animal Agriculture Is Too Little, Too Late
    8. AVMA lauds FDA for new regulation of antibiotics in livestock feed
    9. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
    10. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
    11. Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... Aug. 31, 2015  DICOM Grid,  the #1 ... it was recognized as a semifinalist for a ... The awards are sponsored by Auntminnie.com, a ... in the medical imaging industry.  Since 1999, the ... to acknowledge the contributions of their peers. Nominations ...
    (Date:8/31/2015)... JERUSALEM, Israel, Aug. 31, 2015  Chiasma, Inc. ... company developing octreotide capsules for the orphan condition ... quarter ended June 30, 2015 and provided a ... have been a transformative time for Chiasma, as ... recently announced that our first New Drug Application ...
    (Date:8/31/2015)... Thousands of people will peacefully demonstrate their ... addiction epidemic at dozens of rallies across the country ... the United States has experienced skyrocketing ... and heroin, yet the President has never once spoken ... letter to President Obama , rally organizers compared his ...
    Breaking Medicine Technology:DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
    (Date:8/31/2015)... ... ... When it comes to undergoing a hair transplant, most patients have donor hair moved from ... to the hair on top of the scalp, as well as filling in areas missing ... hair on other areas of their head. , What about patients who have a limited, ...
    (Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a ... ” tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits ... to help India Network members make an informed decision regarding the care they ...
    (Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... The ... that Firm Partner William Scott has been nominated by his peers to earn a ... less than five percent of attorneys in the state of Illinois. The nomination process ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ... one-day event geared to patients and family members, medical professionals, and researchers, covering ... mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... ... Vice President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic ... is an industry leader in consumer-focused programs that have contributed to the company’s ...
    Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
    ... U.S. hospitals and doctors competing on the ... basis of quality, cost and service., ... specialty network for high value medical procedures such as coronary,artery ... excellence throughout the United States. These providers and facilities,meet specific ...
    ... Medicare Part D has improved drug,coverage and lessened ... says a new study released today by Avalere Health ... the first to use a large, national claims dataset ... utilization and,out-of-pocket costs for enrollees with type 2 diabetes. ...
    ... five-year study at the University of Texas Medical Branch ... two most common diseases of young children: colds and ... March 15 issue of Clinical Infectious Disease, confirmed the ... of young children, viral colds and ear infections. It ...
    ... ATLANTAThe American Cancer Society invites medical and science reporters to ... York City to learn whats new in the fight against ... the American Cancer Society. This informative media briefing will offer ... as in cancer research, prevention, early detection, patient services, and ...
    ... Orthotopic liver transplantation (OLT) is associated with severe bleeding ... this severe bleeding in OLT. Hemostatic abnormalities remain a ... led by Professor Wang Xuehao, is to be published ... Journal of Gastroenterology. , Aprotinin, a serine protease inhibitor, ...
    ... Administrator to U.S. Insurers Strengthens its ... Providers, Physicians and Patients, BERKELEY HEIGHTS, N.J., ... ), a worldwide provider of secure workflow,management software ... of the nation,s leading mobility benefit providers to,national ...
    Cached Medicine News:Health News:The Healthplace America(TM) Benefit Delivers a Better Option in Healthcare 2Health News:Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the 'Donut Hole' 2Health News:Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the 'Donut Hole' 3Health News:Researchers confirm link between common cold and ear infection 2Health News:American Cancer Society science reporters briefing to feature latest developments in cancer 2Health News:American Cancer Society science reporters briefing to feature latest developments in cancer 3Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 2Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 3Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 4
    This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
    For the quantitative in vitro determination of Potassium in serum or plasma....
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    For the quantitative in vitro determination of Valproic Acid in human serum...
    Medicine Products: